BRAF and melanoma: Vemurafenib monotherapy was recently compared to the combination of dabrafenib plus trametinib in an open-label, randomized, phase III trial of previously untreated patients with unresectable stage IIIc or IV melanoma with BRAF V600E or V600K mutations.